GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (NAS:ALZN) » Definitions » Preferred Stock

ALZN (Alzamend Neuro) Preferred Stock : $0.00 Mil (As of Jul. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Alzamend Neuro's preferred stock for the quarter that ended in Jul. 2024 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Alzamend Neuro's Enterprise Value for the quarter that ended in Jul. 2024 was $1.88 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Alzamend Neuro's Book Value per Share for the quarter that ended in Jul. 2024 was $-1.41.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Alzamend Neuro's Earnings per Share (Diluted) for the three months ended in Jul. 2024 was $-1.25.


Alzamend Neuro Preferred Stock Historical Data

The historical data trend for Alzamend Neuro's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzamend Neuro Preferred Stock Chart

Alzamend Neuro Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Preferred Stock
Get a 7-Day Free Trial - - - - -

Alzamend Neuro Quarterly Data
Apr19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alzamend Neuro Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Alzamend Neuro  (NAS:ALZN) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Alzamend Neuro's Enterprise Value for the quarter that ended in Jul. 2024 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Alzamend Neuro's Book Value per Share for the quarter that ended in Jul. 2024 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Alzamend Neuro's Earnings per Share (Diluted) (EPS) for the three months ended in Jul. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzamend Neuro Preferred Stock Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzamend Neuro Business Description

Traded in Other Exchanges
N/A
Address
3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Executives
Ault Milton C Iii 10 percent owner 11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141
David J Katzoff officer: Chief Operating Officer 201 SHIPYARD WAY, NEWPORT BEACH CA 92663
Stephan Jackman director, officer: Chief Executive Officer C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Lynne Fahey Mcgrath director 28145 CEDAR POINT RD., EASTON MD 21601
Mark Gustafson director 10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9
William B. Horne director C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626
Henry Carl Nisser director, officer: Exec VP and General Counsel 100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017
Kenneth S Cragun officer: SVP of Finance 3775 CHIPPEWA CIRCLE, CORONA CA 92881
Jeffrey Oram director 15 ORCHARD STREET, MENDHAM NJ 07945
Escalona Lien officer: Chief Financial Officer C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Andrew H. Woo director 2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404

Alzamend Neuro Headlines

From GuruFocus

Alzamend Neuro Announces Reverse Stock Split

By Business Wire 07-12-2024